Is It Time to Use De Novo mTOR Inhibitors Posttran

Authors: Greg J McKenna

Publish Date: 2016/07/29

Volume: 3, Issue: 3, Pages: 244-253

PDF Link

Abstract

The use of mTOR inhibitors evokes debate in transplantation Numerous clinical trials have explored the role of the mTOR inhibitors sirolimus and everolimus in kidney transplantation but the results have been mixed they have not shown a clear benefit over the current regimens However many of these trials were impacted by the difficulties and uncertainties in managing side effects and the dosing of the mTOR inhibitors Being aware of the effective treatments available for these side effects understanding the pathophysiology of the mTOR pathway allows patients to remain on therapy Successful side effect management means that the longer term advantageous benefits of mTOR inhibition can be gained by the kidney recipient and means that it is time to use de novo mTOR inhibitors in kidney recipients

Keywords: